Impacto del tratamiento con irbesartán sobre la reducción del riesgo cardiovascular de pacientes hipertensos en España. Estudio KORAL-HTA

Medrano, 2005, Factores de riesgo cardiovascular en la población española: metaanálisis de estudios transversales, Med Clin (Barc), 124, 606, 10.1157/13074389 Álvarez-Sala, 2005, Estudio PREVENCAT: control del riesgo cardiovascular en Atención Primaria, Med Clin (Barc), 124, 406, 10.1157/13072841 Banegas, 2002, Hypertension magnitude and management in the elderly population of Spain, J Hypertens, 20, 2157, 10.1097/00004872-200211000-00014 Juanatey, 2001, Impacto de la hipertensión en las cardiopatías en España. Estudio Cardiotens 1999, Rev Esp Cardiol, 54, 139, 10.1016/S0300-8932(01)76284-7 Banegas, 1999, Mortalidad relacionada con la hipertensión y la presión arterial en España, Med Clin (Barc), 112, 489 Banegas, 2004, Blood pressure control and physician management of hypertension in hospital hypertension units in Spain, Hypertension, 43, 1338, 10.1161/01.HYP.0000127424.59774.84 Coca, 2002, Evolución del control de la hipertensión arterial en España. Resultados del estudio Controlpres 2001, Hipertensión, 19, 390 Llisterri Caro, 2004, Control de la presión arterial en la población hipertensa española atendida en Atención Primaria. Estudio PRESCAP 2002, Med Clin (Barc), 122, 165, 10.1157/13057821 Zanchetti, 1997, The hypertensive patient with multiple risk factors: is treatment really so difficult?, Am J Hypertens, 10, 223S, 10.1016/S0895-7061(97)00327-0 Stamler, 1986, Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356.222 primary screenees of the Multiple Risk Factors Intervention Trial (MRFIT), JAMA, 256, 2823, 10.1001/jama.1986.03380200061022 Marín, 2005, Guías sobre el diagnóstico y tratamiento de la hipertensión arterial en España 2005, Med Clin (Barc), 125, 24, 10.1157/13076402 2003, 2003 European Society of Hypertension-European Society of Cardiology. Guidelines for the management of arterial hypertension, J Hypertension, 21, 1011, 10.1097/00004872-200306000-00001 Chobanian, 2003, The JNC 7 Report, JAMA, 289, 2560, 10.1001/jama.289.19.2560 Gerstein, 2001, Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals, JAMA, 286, 421, 10.1001/jama.286.4.421 Hillege, 2002, Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population, Circulation, 106, 1777, 10.1161/01.CIR.0000031732.78052.81 Stehouwer, 1992, Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus, Lancet, 340, 319, 10.1016/0140-6736(92)91401-S Stehouwer, 1997, Endothelial dysfunction and pathogenesis of diabetic angiopathy, Cardiovasc Res, 34, 55, 10.1016/S0008-6363(96)00272-6 Festa, 2000, Inflammation and microalbuminuria in nondiabetic and type 2 diabetic subjects: the insulin resistance atherosclerosis study, Kidney Int, 58, 1703, 10.1046/j.1523-1755.2000.00331.x DelĺOmo, 2002, Association between high-normal albuminuria and risk factors for cardiovascular and renal disease in essential hypertensive mens, Am J Kidney Dis, 40, 1, 10.1053/ajkd.2002.33906 Ibsen, 2005, Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients: Losartan Intervention for Endpoint Reduction in Hypertension Study, Hypertension, 45, 198, 10.1161/01.HYP.0000154082.72286.2a Marrugat, 2003, Estimación del riesgo coronario en España mediante la ecuación de Framingham calibrada, Rev Esp Cardiol, 56, 253, 10.1157/13043951 Parving, 2001, The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes, N Engl J Med, 345, 870, 10.1056/NEJMoa011489 Lewis, 2001, Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes, N Engl J Med, 345, 851, 10.1056/NEJMoa011303 De Álvaro, 2005, Microalbuminuria in hypertensive patients: evaluation of one-year treatment with irbesartan, Kidney Int Suppl, 93, S29, 10.1111/j.1523-1755.2005.09307.x 1999, J Hypertens, 17, 151 Sans, 2001, Tendencias de la prevalencia, conocimiento, tratamiento y control de la hipertensión arterial entre 1986 y 1996: estudio MONICA-Cataluña, Med Clin (Barc), 117, 246, 10.1016/S0025-7753(01)72077-5 Bakris, 2001, A practical approach to achieving recommended blood pressure goals in diabetic patients, Arch Intern Med, 161, 2661, 10.1001/archinte.161.22.2661 Bragulat, 2003, Effect of long-term irbesartan treatment on endothelium-dependent vasodilation in essential hypertensive patients, Br J Biomed Sci, 60, 191, 10.1080/09674845.2003.11783698 Coca, 2003, Once-daily fixed-combination irbesartan 300 mg/hydrochlorothiazide 25 mg and circadian blood pressure profile in patients with essential hypertension, Clin Ther, 25, 2849, 10.1016/S0149-2918(03)80338-7 Coca, 2003, Efecto del tratamiento antihipertensivo con irbesartán sobre el riesgo cardiovascular absoluto, Rev Clin Esp, 203, 183, 10.1157/13045538 Cristóbal, 2005, Ecuación de Framingham de Wilson y ecuación de REGICOR. Estudio comparativo, Rev Esp Cardiol, 58, 910, 10.1157/13078127 Klausen, 2004, Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes, Circulation, 110, 32, 10.1161/01.CIR.0000133312.96477.48 Bramlage, 2004, The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: an observational study in 16600 patients in Primary Care, Cur Med Res Opin, 20, 1625, 10.1185/030079904X3861 Bramlage, 2004, Hypertension in overweight and obese Primary Care patients is highly prevalent and poorly controlled, Am J Hypertens, 17, 904, 10.1016/j.amjhyper.2004.05.017